Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

Expression profiling of ion channel genes predicts clinical outcome in breast cancer

Authors: Jae-Hong Ko, Eun A Ko, Wanjun Gu, Inja Lim, Hyoweon Bang, Tong Zhou

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Ion channels play a critical role in a wide variety of biological processes, including the development of human cancer. However, the overall impact of ion channels on tumorigenicity in breast cancer remains controversial.

Methods

We conduct microarray meta-analysis on 280 ion channel genes. We identify candidate ion channels that are implicated in breast cancer based on gene expression profiling. We test the relationship between the expression of ion channel genes and p53 mutation status, ER status, and histological tumor grade in the discovery cohort. A molecular signature consisting of ion channel genes (IC30) is identified by Spearman’s rank correlation test conducted between tumor grade and gene expression. A risk scoring system is developed based on IC30. We test the prognostic power of IC30 in the discovery and seven validation cohorts by both Cox proportional hazard regression and log-rank test.

Results

22, 24, and 30 ion channel genes are found to be differentially expressed with a change in p53 mutation status, ER status, and tumor histological grade in the discovery cohort. We assign the 30 tumor grade associated ion channel genes as the IC30 gene signature. We find that IC30 risk score predicts clinical outcome (P < 0.05) in the discovery cohort and 6 out of 7 validation cohorts. Multivariate and univariate tests conducted in two validation cohorts indicate that IC30 is a robust prognostic biomarker, which is independent of standard clinical and pathological prognostic factors including patient age, lymph node status, tumor size, tumor grade, estrogen and progesterone receptor status, and p53 mutation status.

Conclusions

We identified a molecular gene signature IC30, which represents a promising diagnostic and prognostic biomarker in breast cancer. Our results indicate that information regarding the expression of ion channels in tumor pathology could provide new targets for therapy in human cancers.
Appendix
Available only for authorised users
Literature
1.
2.
Camerino DC, Tricarico D, Desaphy JF: Ion channel pharmacology. Neurotherapeutics. 2007, 4: 184-198.CrossRefPubMed
3.
Camerino DC, Desaphy JF, Tricarico D, Pierno S, Liantonio A: Therapeutic approaches to ion channel diseases. Adv Genet. 2008, 64: 81-145.CrossRefPubMed
4.
5.
Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D: GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998, 14: 656-664.CrossRefPubMed
6.
Fiske JL, Fomin VP, Brown ML, Duncan RL, Sikes RA: Voltage-sensitive ion channels and cancer. Cancer Metastasis Rev. 2006, 25: 493-500.CrossRefPubMed
7.
Roger S, Potier M, Vandier C, Besson P, Le Guennec JY: Voltage-gated sodium channels: new targets in cancer therapy?. Curr Pharm Des. 2006, 12: 3681-3695.CrossRefPubMed
8.
Jentsch TJ, Hubner CA, Fuhrmann JC: Ion channels: function unravelled by dysfunction. Nat Cell Biol. 2004, 6: 1039-1047.CrossRefPubMed
9.
Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D: GeneCards: integrating information about genes, proteins and diseases. Trends Genet. 1997, 13: 163-CrossRefPubMed
10.
Lehmann-Horn F, Jurkat-Rott K: Voltage-gated ion channels and hereditary disease. Physiol Rev. 1999, 79: 1317-1372.PubMed
11.
Le Guennec JY, Ouadid-Ahidouch H, Soriani O, Besson P, Ahidouch A, Vandier C: Voltage-gated ion channels, new targets in anti-cancer research. Recent Pat Anticancer Drug Discov. 2007, 2: 189-202.CrossRefPubMed
12.
Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, Stuhmer W: Role of voltage-gated potassium channels in cancer. J Membr Biol. 2005, 205: 115-124.CrossRefPubMed
13.
14.
15.
Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A. 2005, 102: 13550-13555.PubMedCentralCrossRefPubMed
16.
Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M, Lane L, Birnbaum D, Bertucci F: Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One. 2011, 6: e27656-PubMedCentralCrossRefPubMed
17.
18.
Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L, Huang F, Klaar S: Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res. 2005, 7: R953-R964.PubMedCentralCrossRefPubMed
19.
Kao KJ, Chang KM, Hsu HC, Huang AT: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer. 2011, 11: 143-PubMedCentralCrossRefPubMed
20.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J: Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005, 365: 671-679.CrossRefPubMed
21.
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009.CrossRefPubMed
22.
Benjamini Y, Hochberg Y: Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995, 57: 289-300.
23.
24.
Sontheimer H: An unexpected role for ion channels in brain tumor metastasis. Exp Biol Med (Maywood). 2008, 233: 779-791. 10.3181/0711-MR-308.CrossRef
25.
26.
27.
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H: A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011, 305: 1873-1881.CrossRefPubMed
28.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90.CrossRefPubMed
29.
Bertheau P, Espie M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de The H: TP53 status and response to chemotherapy in breast cancer. Pathobiology. 2008, 75: 132-139.CrossRefPubMed
30.
Soussi T: p53 alterations in human cancer: more questions than answers. Oncogene. 2007, 26: 2145-2156.CrossRefPubMed
31.
Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganas M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J: Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol. 2005, 16: 743-748.CrossRefPubMed
32.
33.
Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD: P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer. 2002, 100: 290-296.CrossRefPubMed
34.
Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 2008, 68: 5405-5413.CrossRefPubMed
35.
Troester MA, Herschkowitz JI, Oh DS, He X, Hoadley KA, Barbier CS, Perou CM: Gene expression patterns associated with p53 status in breast cancer. BMC Cancer. 2006, 6: 276-PubMedCentralCrossRefPubMed
36.
Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G: Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol. 2006, 17: 1504-1511.CrossRefPubMed
37.
Sirvent JJ, Salvado MT, Santafe M, Martinez S, Brunet J, Alvaro T, Palacios J: p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol. 1995, 10: 531-539.PubMed
38.
Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S: Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012, 7: e46104-PubMedCentralCrossRefPubMed
39.
Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, Chen H, Omeroglu G, Meterissian S, Omeroglu A: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008, 14: 518-527.CrossRefPubMed
40.
Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M: Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011, 108: 7160-7165.PubMedCentralCrossRefPubMed
41.
Saadi A, Shannon NB, Lao-Sirieix P, O’Donovan M, Walker E, Clemons NJ, Hardwick JS, Zhang C, Das M, Save V: Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci U S A. 2010, 107: 2177-2182.PubMedCentralCrossRefPubMed
42.
Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004, 350: 1828-1837.CrossRefPubMed
43.
Pedersen SF, Stock C: Ion channels and transporters in cancer: Pathophysiology, regulation and clinical potential. Cancer Res. 2013, 73: 1658-1661.CrossRefPubMed
44.
Prevarskaya N, Skryma R, Shuba Y: Ion channels and the hallmarks of cancer. Trends Mol Med. 2010, 16: 107-121.CrossRefPubMed
45.
Ouadid-Ahidouch H, Ahidouch A: K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membr Biol. 2008, 221: 1-6.CrossRefPubMed
46.
Wonderlin WF, Strobl JS: Potassium channels, proliferation and G1 progression. J Membr Biol. 1996, 154: 91-107.CrossRefPubMed
47.
Hemmerlein B, Weseloh RM, Mello de Queiroz F, Knotgen H, Sanchez A, Rubio ME, Martin S, Schliephacke T, Jenke M, Heinz Joachim R: Overexpression of Eag1 potassium channels in clinical tumours. Mol Cancer. 2006, 5: 41-PubMedCentralCrossRefPubMed
48.
Stuhmer W, Alves F, Hartung F, Zientkowska M, Pardo LA: Potassium channels as tumour markers. FEBS Lett. 2006, 580: 2850-2852.CrossRefPubMed
49.
Mu D, Chen L, Zhang X, See LH, Koch CM, Yen C, Tong JJ, Spiegel L, Nguyen KC, Servoss A: Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell. 2003, 3: 297-302.CrossRefPubMed
50.
Stringer BK, Cooper AG, Shepard SB: Overexpression of the G-protein inwardly rectifying potassium channel 1 (GIRK1) in primary breast carcinomas correlates with axillary lymph node metastasis. Cancer Res. 2001, 61: 582-588.PubMed
51.
Abdul M, Santo A, Hoosein N: Activity of potassium channel-blockers in breast cancer. Anticancer Res. 2003, 23: 3347-3351.PubMed
52.
Haren N, Khorsi H, Faouzi M, Ahidouch A, Sevestre H, Ouadid-Ahidouch H: Intermediate conductance Ca2+ activated K+ channels are expressed and functional in breast adenocarcinomas: correlation with tumour grade and metastasis status. Histol Histopathol. 2010, 25: 1247-1255.PubMed
53.
Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, Couraud PO, Ningaraj NS: Role of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC Cancer. 2009, 9: 258-PubMedCentralCrossRefPubMed
54.
Suh KS, Malik M, Shukla A, Yuspa SH: CLIC4, skin homeostasis and cutaneous cancer: surprising connections. Mol Carcinog. 2007, 46: 599-604.CrossRefPubMed
55.
Walia V, Ding M, Kumar S, Nie D, Premkumar LS, Elble RC: hCLCA2 is a p53-inducible inhibitor of breast cancer cell proliferation. Cancer Res. 2009, 69: 6624-6632.PubMedCentralCrossRefPubMed
56.
Gruber AD, Pauli BU: Tumorigenicity of human breast cancer is associated with loss of the Ca2+ -activated chloride channel CLCA2. Cancer Res. 1999, 59: 5488-5491.PubMed
57.
Jentsch TJ, Stein V, Weinreich F, Zdebik AA: Molecular structure and physiological function of chloride channels. Physiol Rev. 2002, 82: 503-568.CrossRefPubMed
58.
Wang XT, Nagaba Y, Cross HS, Wrba F, Zhang L, Guggino SE: The mRNA of L-type calcium channel elevated in colon cancer: protein distribution in normal and cancerous colon. Am J Pathol. 2000, 157: 1549-1562.PubMedCentralCrossRefPubMed
59.
Oguro-Okano M, Griesmann GE, Wieben ED, Slaymaker SJ, Snutch TP, Lennon VA: Molecular diversity of neuronal-type calcium channels identified in small cell lung carcinoma. Mayo Clin Proc. 1992, 67: 1150-1159.CrossRefPubMed
60.
Aydar E, Yeo S, Djamgoz M, Palmer C: Abnormal expression, localization and interaction of canonical transient receptor potential ion channels in human breast cancer cell lines and tissues: a potential target for breast cancer diagnosis and therapy. Cancer Cell Int. 2009, 9: 23-PubMedCentralCrossRefPubMed
61.
Peters AA, Simpson PT, Bassett JJ, Lee JM, Da Silva L, Reid LE, Song S, Parat MO, Lakhani SR, Kenny PA: Calcium channel TRPV6 as a potential therapeutic target in estrogen receptor-negative breast cancer. Mol Cancer Ther. 2012, 11: 2158-2168.CrossRefPubMed
62.
63.
Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A: TRP channels: diagnostic markers and therapeutic targets for breast cancer?. Trends Mol Med. 2013, 19: 117-124.CrossRefPubMed
64.
Ouadid-Ahidouch H, Dhennin-Duthille I, Gautier M, Sevestre H, Ahidouch A: TRP calcium channel and breast cancer: expression, role and correlation with clinical parameters. Bull Cancer. 2012, 99: 655-664.PubMed
65.
Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z: Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res. 2005, 11: 5381-5389.CrossRefPubMed
66.
Brisson L, Gillet L, Calaghan S, Besson P, Le Guennec JY, Roger S, Gore J: Na(V)1.5 enhances breast cancer cell invasiveness by increasing NHE1-dependent H(+) efflux in caveolae. Oncogene. 2011, 30: 2070-2076.CrossRefPubMed
67.
Diss JK, Stewart D, Pani F, Foster CS, Walker MM, Patel A, Djamgoz MB: A potential novel marker for human prostate cancer: voltage-gated sodium channel expression in vivo. Prostate Cancer Prostatic Dis. 2005, 8: 266-273.CrossRefPubMed
68.
Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A: Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem. 2009, 16: 66-93.CrossRefPubMed
69.
Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, Lalmanach G, Le Guennec JY: Voltage-gated sodium channel activity promotes cysteine cathepsin-dependent invasiveness and colony growth of human cancer cells. J Biol Chem. 2009, 284: 8680-8691.PubMedCentralCrossRefPubMed
70.
Diss JK, Fraser SP, Djamgoz MB: Voltage-gated Na+ channels: multiplicity of expression, plasticity, functional implications and pathophysiological aspects. Eur Biophys J. 2004, 33: 180-193.PubMed
71.
Maier T, Schmidt A, Guell M, Kuhner S, Gavin AC, Aebersold R, Serrano L: Quantification of mRNA and protein and integration with protein turnover in a bacterium. Mol Syst Biol. 2011, 7: 511-PubMedCentralCrossRefPubMed
72.
Goncalves RP, Buzhynskyy N, Prima V, Sturgis JN, Scheuring S: Supramolecular assembly of VDAC in native mitochondrial outer membranes. J Mol Biol. 2007, 369: 413-418.CrossRefPubMed
73.
Grills C, Jithesh PV, Blayney J, Zhang SD, Fennell DA: Gene expression meta-analysis identifies VDAC1 as a predictor of poor outcome in early stage non-small cell lung cancer. PLoS One. 2011, 6: e14635-PubMedCentralCrossRefPubMed
74.
Sharman JL, Mpamhanga CP, Spedding M, Germain P, Staels B, Dacquet C, Laudet V, Harmar AJ: IUPHAR-DB: new receptors and tools for easy searching and visualization of pharmacological data. Nucleic Acids Res. 2011, 39: D534-D538.PubMedCentralCrossRefPubMed
75.
Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F: A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc. 2004, 99: 909-917. 10.1198/016214504000000683.CrossRef
Metadata
Title
Expression profiling of ion channel genes predicts clinical outcome in breast cancer
Authors
Jae-Hong Ko
Eun A Ko
Wanjun Gu
Inja Lim
Hyoweon Bang
Tong Zhou
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-106

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration

Research

The long non-coding RNA ERIC is regulated by E2F and modulates the cellular response to DNA damage

Research

Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia - implications on constitutive activation of NFκB pathway

Research

Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells

Research

Novel mechanism of regulation of fibrosis in kidney tumor with tuberous sclerosis

Research

Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: emerging functional associations
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits